ArticleFrontiers in immunology2025
Association of systemic inflammatory factors with clinical outcomes in patients with autoimmune encephalitis at different clinical stages.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Our study aimed to explore the association of systemic inflammatory factors in relations to disease severity of the cell surface antibody-mediated autoimmune encephalitis (AE) across various stages. Methods: We retrospectively analyzed patients with AE from two hospitals between October 2016 and December 2023. Systemic inflammatory factors were measured at admission and discharge. Disease severity and prognosis were assessed using the clinical assessment scale for autoimmune encephalitis (CASE), and multivariate logistic regression analysis was used to identify associated risk factors. Results: A total 83 patients were enrolled. The CASE score and the modified Rankin Scale score were positively correlated at admission, discharge and follow-up (r=0.937, P < 0.001; r=0.910, P < 0.001; r=0.972, P < 0.001). Multivariate logistic regression analysis revealed that a higher systemic immune-inflammation index (SII) at admission (OR=27.617, 95% CI: 1.060-719.699, P=0.046) and an elevated platelet-to-lymphocyte ratio (PLR) at discharge (OR=11.373, 95% CI: 1.166-110.893, P=0.036) were independent risk factors for severe disease at admission and discharge, respectively. Additionally, a high neutrophil-to-platelet ratio (NPR) at either admission (OR=10.384, 95% CI: 2.036-52.958, P=0.005) or discharge (OR=5.714, 95% CI: 1.189-27.455, P=0.036) was associated with poor prognosis. Conclusions: SII and PLR were associated with disease severity, while NPR was a consistent predictor of poor long-term outcomes. These findings highlight the value of systemic inflammatory factors in monitoring disease progression and guiding treatment decisions in patients with AE mediated by cell surface antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.